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Available online 28 September 2016Mutations in presenilin 1 (PSEN1) lead to themost aggressive form of familial Alzheimer's disease (AD). Human
induced pluripotent stem cells (hiPSCs) derived from AD patients can be differentiated and used for disease
modeling. Here, we derived hiPSC from skin ﬁbroblasts obtained from an AD patient carrying a L282F mutation
in PSEN1. We transfected skin ﬁbroblasts with episomal iPSC reprogramming vectors targeting human OCT4,
SOX2, L-MYC, KLF4, NANOG, LIN28, and short hairpin RNA against TP53. Our hiPSC line, L282F-hiPSC, displayed
typical stem cell characteristicswith consistent expression of pluripotency genes and the ability to differentiation
into the three germ layers.
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A human induced pluripotent stem cell (hiPSC) line was generated
from skin ﬁbroblasts collected from a familial 64-year-old male
Alzheimer's disease (AD) patient carrying a heterozygous L282F muta-
tion in the presenilin 1 (PSEN1) gene. The underlying C→ T transversion
at the ﬁrst position of codon 282 (Chr14:73198105, Ensembl genome
assembly: GRCh38.p7) results in the substitution of leucine (L) to phe-
nylalanine (F) as previously described (Hamaguchi et al., 2009). We
conﬁrmed the presence of this L282F mutation in patient ﬁbroblasts
through sequencing (Fig. 1A). In addition, we detected a heterozygous
variation (Chr14: 73198104 GNA) in our patient (Fig. 1A). Genetic var-
iation at this position does not lead to any changes at the amino acid
level andhas been previously reported as a silent single nucleotide poly-
morphism (The 1000 Genomes Project Consortium, 2015).
To derive hiPSC frompatientﬁbroblasts,we adopted previous proto-
cols (Okita et al., 2011; Rasmussen et al., 2014) and electroporated the
patient's skin ﬁbroblasts with episomal plasmids expressing human
OCT4, SOX2, L-MYC, KLF4, NANOG, LIN28, and short hairpin RNA against
TP53. To demonstrate that our established hiPSC line, referred to as
L282F-hiPSC, was free of integrated episomal reprogramming factors,
we performed quantitative PCR with primers targeting OCT4, SOX2,
and LIN28 from the episomal plasmids (Fig. 1B). L282F-hiPSCswas char-
acterized to be karyotypically normal (Fig. 1C), morphologically resem-
bled stem cells, and expressed pluripotency markers including OCT4,
NANOG, SSEA4, TRA-1-60, and TDGF1 (Fig. 1D & E). Pluripotency of
L282F-hiPSC was further supported by its ability to differentiate intoC-ND license
Fig. 1. A Sequencing of PSEN1 conﬁrmed the heterozygous L282 point mutation at position Chr14:73198105 CNT (arrow) in the AD patient cells. An additional variation at position
Chr14:73198104 GNA was also detected (*). B. No integration of reprogramming factors was detected in the L282F-hiPSC. Quantitative PCR using plasmid-speciﬁc primers of the
episomal reprogramming factors (OCT4, SOX2, and LIN28) was performed on DNA samples from L282F-hiPSCs, non-reprogrammed ﬁbroblasts, and a positive control with presence of
all reprogramming factors. All quantitative expression data were normalized to the expression levels of GAPDH. C. Representative normal karyotype of L282F-hiPSC with 46,XY. D.
Quantitative RT-PCR analysis of pluripotency in L282F-hiPSC. A panel of pluripotency-associated genes commonly expressed in stem cells was examined (x-axis). The y-axis shows the
relative fold change (2-△△Ct) in transcript expression of L282F-hiPSC over ﬁbroblasts. All quantitative gene expression data were normalized to the expression levels of GAPDH. E.
Immunoﬂuorescence staining of L282F-iPSCs with pluripotency markers: OCT4, NANOG, SSEA3, SSEA4, TRA1-60 and TRA1-81. Scale bars correspond to 100 μm. F. In vitro
differentiation of L282F-hiPSC derived embryoid bodies on day 21. Cells were stained with smooth muscle actin (SMA), α-fetoprotein (AFP), and β-III tubulin (TUJI). Scale bars
correspond to 100 μm.
471A. Poon et al. / Stem Cell Research 17 (2016) 470–473all three germ layers with positive staining for ectodermal marker β-tu-
bulin III, mesodermal marker smoothmuscle actin, and the endodermal
marker α-fetoprotein (Fig. 1F).The study was approved by the Ethics Committee of the Capital Re-
gion of Denmark (protocol number H-4-2011-157) and informed con-
sent was obtained from the patient.
Fig. 1 (continued).
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Reprogramming of ﬁbroblasts into hiPSCs
Fibroblasts from a skin biopsy of a 64-year-oldmanwere cultured in
DMEM supplemented with 10% fetal bovine serum, 1% Glutamine, and2 ng/ml of ﬁbroblast growth factor 2. Fibroblasts (1 × 105 cells) were
electroporated with 1 μg of episomal plasmids containing gene se-
quences for human OCT4, SOX2, KLF4, L-MYC, LIN-28 and short hairpin
RNA for TP53 (Addgene) using the Neon transfection system (Thermo
Fisher Scientiﬁc). After electroporation, cells were cultured on Matrigel
(BD Biosciences) in Essential 8 medium (E8, Thermo Fisher Scientiﬁc).
Table 1
A list of primary antibodies used for immunoﬂuorescence staining.
Antibody and host species Dilution Company and
catalog number
Pluripotency Rabbit anti-NANOG 1:50 Peprotech, 500-P236
Goat anti-OCT4 1:100 Santa Cruz, sc-8628
Rat anti-SSEA3 1:100 Biolegend, 330,302
Mouse anti-SSEA4 1:100 Biolegend, 330,402
Mouse anti-Tra-1-60 1:200 Biolegend, 330,602
Mouse anti-Tra-1-81 1:200 Biolegend, 330,702
In vitro
differentiation
Rabbit anti-α-1-fetoprotein
(AFP)
1:100 DAKO, A0008
Mouse anti-Smooth muscle
Actin (SMA) 1:500
1:100 DAKO, M0851
Mouse anti-β-III tubulin (TUJI) 1:1000 Sigma-Aldrich, T8660
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transferred to Matrigel-coated dishes in E8 medium. The hiPSC lines
were routinely passaged using 0.5 mM EDTA (Sigma) and frozen as
stocks in E8 containing 10% DMSO.
Sequencing analysis
Genotyping of PSEN1mutation was performed by PCR ampliﬁcation
using a primer pair spanning the L282F mutation in exon 8 of PSEN1
(forward primer: 5′-ccaccagttcacctgccattt-3′ and reverse primer: 5′-
tggaactcctgcagatctctt-3′). PCR was performed using Taq DNA polymer-
ase (Takara) according to the manufacturer's instructions. Amplicons
were sequenced and electropherograms were analyzed with an ABI
PRISM310 Genetic Analyzer.
Karyotyping
L282F-hiPSCs were karyotyped using standard cytogenetic proce-
dures. In brief, cells were treated for 45 min with KaryoMAX colcemid
(Thermo Fisher Scientiﬁc), harvested in fresh ﬁxative consisted of 25%
acetic acid and 75% methanol, and subjected for G-band karyotyping
at the Institute of Medical Genetics and Applied Genomics (University
of Tübingen, Tübingen, Germany).
Reprogramming factors integration assay
Genomic DNA was isolated from passage 10 L282F-hiPSCs, non-
reprogrammed ﬁbroblasts as negative control, and ﬁbroblasts collected
48 h after electroporation with episomal plasmids as a positive control.
Quantitative PCR was carried out using primers speciﬁc to the episomal
plasmids (Okita et al., 2011). All quantitative expression data were nor-
malized to the expression levels of GAPDH.
Quantitative reverse transcription PCR analysis of pluripotency genes
Total RNA was puriﬁed from L282F-hiPSCs and ﬁbroblasts using
RNeasy Mini Kit (Qiagen) and converted to cDNA using High-Capac-
ity cDNA Reverse Transcription Kit (Thermo Fisher Scientiﬁc). Real-
time quantitative reverse transcription PCR (qRT-PCR) was per-
formed using the StepOnePlus system (Thermo Fisher Scientiﬁc).
Applied Biosystems' TaqMan assays was used to measure the ex-
pression of speciﬁc pluripotency genes including NANOG (assay
no.: HS02387400_g1), TDGF1 (assay no.: HS02339497_g1), GABRB3
(assay no.: HS00241459_m1), GDF3 (assay no.: HS00220998_m1),
DNMT3B (assay no.: HS00171876_m1), and GAPDH (assay no.:
Hs03929097_g1). All quantitative gene expression data were nor-
malized to the expression levels of GAPDH. The relative fold changes
(2-△△Ct) in transcript expression of L282F-hiPSC over ﬁbroblasts
were calculated.
Immunoﬂuorescence staining
L282F-hiPSCswere ﬁxedwith 4% paraformaldehyde (PFA) in PBS for
15min, blocked, and incubatedwith primary antibodies listed in Table 1
overnight at 4 °C. The next day, cells were incubated with the appropri-
ate secondary antibodies and counterstained with DAPI. Images were
acquired using the Leica DMRB-ﬂuorescence microscope.
In vitro differentiation by embryoid body (EB) formation
Embryoid body (EB) formation was performed by transferring
Dispase-treated clumps of hiPSCs onto ultra-low attachment plates(Corning) in E8. After 2 days of culture, the medium was changed to
DMEM/F12 containing 20% knockout serum replacement (Thermo Fish-
er Scientiﬁc), 1 × nonessential amino acid, 2mM L-glutamine, 0.1mM2-
mercaptoethanol, and 1%pen/strep. After 7 days, the EBswere plated on
Matrigel-coated culture dishes and cultured in DMEM supplemented
with 10% FBS, 2 mM L-glutamine and 1% pen/strep for up to three
weeks. The cells were ﬁxed for 15 min in 4% PFA for immunoﬂuores-
cence staining with the antibodies TUJI, SMA and AFP (Table 1).
Veriﬁcation and authentication
L282F-hiPSC karyotyping was performed by the Institute of Medical
Genetics andAppliedGenomics, University of Tübingen (Tübingen, Ger-
many). A minimum of 20 metaphases were analyzed. The results
showed a normal 46, XY karyotype without any detectable abnormali-
ties (Fig. 1C). The identity of this line was conﬁrmed by sequencing of
PSEN1 (Fig. 1A), integration assay (Fig. 1B), and expression of several
pluripotency genes as well as genes expressed in the three germ layers
following in vitro differentiation (Fig. 1D–F).
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